Here are the 424B prospectus supplements from Supernus, Inc. (SUPN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SUPN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SUPN filings page.
Indivior Pharmaceuticals, Inc. (INDV) is registering common shares to be issued in an all‑stock merger of equals with Supernus Pharmaceuticals, Inc. Under a fixed 1.5401 exchange ratio, each Supernus share will convert into the right to receive 1.5401 Indivior shares plus cash in lieu of fractional shares, and Supernus will become a wholly owned subsidiary of Indivior. Indivior will then be renamed Supernus, Inc. and its shares will trade on Nasdaq Global Select Market under the ticker “SUPN.”
Indivior will declare a one‑time $1.0 billion Special Dividend for its stockholders and certain equity award holders, payable only if the merger closes. If committed debt financing becomes unavailable but all closing conditions are otherwise satisfied, this may be replaced by an Alternative Dividend of $500 million in cash plus $529.5 million of deferred cash rights. After closing, Indivior stockholders are expected to own approximately 56.5% of the combined company on a fully diluted basis, with former Supernus holders owning about 43.5%. Completion requires approval of the share‑issuance proposal by Indivior stockholders and adoption of the merger agreement by Supernus stockholders at virtual special meetings on October 15, 2026, along with regulatory clearances and other customary conditions.